Alnylam Pharmaceuticals (ALNY) Inventory Average (2018 - 2026)

Alnylam Pharmaceuticals has reported Inventory Average for 9 years, with the latest figure at $83.4 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 15.72% year-over-year to $83.4 million; the trailing twelve-month figure through Mar 2026 stood at $83.4 million (up 15.72% YoY), and the FY2025 full-year result was $80.6 million, down 3.83% from the prior year.
• Inventory Average for Q1 2026 stood at $83.4 million, up from $79.1 million in the prior quarter.
• The five-year high for Inventory Average was $130.4 million in Q1 2023, with the low at $68.6 million in Q2 2025.
• Historically, Inventory Average has averaged $90.7 million across 5 years, with a median of $83.7 million in 2022.
• Annual changes were most pronounced in 2023 — Inventory Average surged 58.2% — and 2024, when it dropped 29.79%.
• Alnylam Pharmaceuticals' Inventory Average stood at $122.2 million in 2022, then decreased by 24.35% to $92.5 million in 2023, then declined by 16.45% to $77.2 million in 2024, then advanced by 2.33% to $79.1 million in 2025, then climbed by 5.47% to $83.4 million in 2026.
• The last three Inventory Average figures came in at $83.4 million (Q1 2026), $79.1 million (Q4 2025), and $73.5 million (Q3 2025), per Business Quant data.